News

This section keeps you updated on any major developments throughout the course of the REPO-TRIAL project.

02 August 2019

Check out our brand new project video on YouTube!

REPO-TRIAL’s scientific coordinator, clinician, and pharmacologist Prof. Dr. Harald Schmidt, the bioinformatics expert and co-coordinator Prof. Dr. Jan Baumbach, the regulatory expert Dr. Hermann Mucke, and Priv.-Doz. Dr. Benedikt Frank, the neurologist overseeing the stroke study, explain the details of the project during an interview session prior to the 2nd GA Meeting in Vienna, Austria, on March 4th, 2019.  We also prepared a German version of the video, see Our Findings.

 

03 July 2019

REPO-TRIAL Coordinator Prof. Harald H.H.W. Schmidt talked about “Symptom- to mechanism-based concepts in medical research, practice and teaching” at the forum ‘Science & Health’ in Fürstenfeldbruck, Germany.

Existing drugs fail to provide benefit for most patients. The efficacy of drug discovery is in a constant decline. This poor translational success of biomedical research is due to false incentives, lack of quality/reproducibility and publication bias. The most important reason, however, is our current concept of disease, i.e. mostly by organ or symptom, not by a mechanism. Systems Medicine will lead to a mechanism-based redefinition of disease, precision diagnosis, and precision therapy – eliminating the need for drug discovery, and completely reorganizing how we teach, train and practice medicine.

“From symptom- to mechanism-based concepts in medical research, practice, and teaching.”

08 May 2019

A new study by Dr. Kleinschnitz, Prof. Dr. Harald Schmidt and REPO-TRIAL colleagues with the title “Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke” has recently been published in the Journal of Clinical Investigation! In May, this study has been covered in form of a separate article in the news section of the Ärzteblatt (renowned German magazine for medical doctors). Congratulations!

12 Feb 2019

REPO-TRIAL Coordinator Dr. Harald H.H.W. Schmidt gave a talk at the World Government Summit in Dubai. View the full presentation on “The End of Medicine as we know it”on YouTube!

06 Mar 2019

2nd GA Meeting held in Vienna: The EU-funded project is now in its 2nd year & brings experts from systems biology, biochemistry, in silico modelling, neurology and cardiology to one table to tackle complex, mechanistically related diseases! From 4-6 March, the REPO-TRIAL group met in Vienna to discuss the next steps of the project.

27 Nov 2018

E. coli gene regulatory networks are inconsistent with gene expression data

This publication, co-authored by Profs. Harald Schmidt and Jan Baumbach and to be published in Nucleic Acids Research, challenges established knowledge of the systemic biology on the cellular level, finding no system-wide correlation between the expression of transcription factors and their target genes in E. coli. More sophisticated network models are needed, with higher complexity and more dynamic features, to truly understand how gene expression is regulated. The preprint version of the paper can be accessed here.

06 Nov 2018
Successful 2nd SC Meeting held in Utrecht: From 5-6 November, the REPO-TRIAL group met in Utrecht to discuss the next steps of the project. Progress has been made in the planning of the REPO-TRIAL Stroke & HFpEF studies and it was great to catch up in person!
01 Oct 2018

Harald Schmidt and Jan Baumbach are keynote speakers at the International Conference on Bioinformatics and Biomedicine (Madrid, 3-6 December 2018).

30 Jul 2018

This September Coordinator Professor Dr. Harald Schmidt will give a talk on “Disease Cluster-based Drug Repurposing” at the International Conference on Network Medicine and Big Data in Rome

18 Jun 2018

We have barely started our 5-year project and are already busy promoting our science!  Ana Casas Guijarro (UM) and Hermann Mucke will hold presentations at the 7th Drug Repositioning, Repurposing and Rescue Conference in Chicago.

Read More

1 Feb 2018

Four different advisory boards, consisting of experts for each topic, will ensure scientific quality, efficient data management and data analysis, as well as adherence to ethical standards, clinical trial regulations, and diversity requirements.

Read more